Sifasi 5000IU Injection is a clinically established pharmaceutical preparation containing CHORIONIC GONADOTROPIN as its primary active ingredient. It falls under the Gynaecology therapeutic class and is widely prescribed for the management of associated medical conditions. Sifasi 5000IU Injection is available in Injection form and is administered as directed by a qualified healthcare professional. The pharmacokinetic profile of CHORIONIC GONADOTROPIN — including absorption, distribution, metabolism, and excretion — has been well-characterized through clinical studies, enabling predictable and reliable dosing in most patient populations. This medicine is classified under the Women's Health general category and the Gynaecology speciality domain. Patients should note that Sifasi 5000IU Injection is a prescription-only medicine and must be used only under the supervision of a licensed physician unless otherwise indicated. Dosage and treatment duration must be individualized based on the patient's clinical condition, age, weight, and concurrent medications.

• Primary Indication: Used to trigger final oocyte maturation and ovulation during infertility treatment, and in the management of hypogonadism. • Combination Therapy: May be used as part of a treatment regimen to achieve desired clinical outcomes. • Maintenance Therapy: Used for ongoing management of gynaecology conditions following initial evaluation. • As Advised: Dosage, frequency, and duration should strictly follow the treating physician's instructions based on individual patient assessment.

Sifasi 5000IU Injection containing CHORIONIC GONADOTROPIN exerts its therapeutic effects through a well-defined pharmacological mechanism relevant to gynaecology conditions. It mimics luteinizing hormone (LH), triggering final follicular maturation and ovulation. Dose adjustments may be required in patients with hepatic dysfunction or specific hormonal profiles. Regular therapeutic monitoring is recommended to ensure optimal treatment response and detect early signs of adverse effects.

• Always inform your doctor about every medicine you are currently taking before starting Sifasi 5000IU Injection — prescription drugs, OTC medications, vitamins, minerals, and herbal products. • Hormonal Agents: Concurrent use with other hormonal preparations may alter efficacy — use only under medical supervision. • Anticoagulants: May interact with blood-thinning medicines — monitor closely if used together. • Enzyme-Inducing Drugs: Certain anticonvulsants and antibiotics may reduce efficacy — inform your doctor. • Carry a complete updated medicine list whenever visiting any healthcare provider to ensure safe prescribing.

Sifasi 5000IU Injection is a prescription-only medicine (Schedule H / H1 or equivalent, where applicable) and should not be purchased or used without appropriate medical guidance. Storage: Store below 25°C away from direct sunlight and moisture. Refrigerate (2–8°C) if indicated on pack. Keep out of reach of children. Disposal: Do not flush unused medicines or dispose in household waste; return unused or expired medicines to a licensed pharmacy. Pharmacovigilance: Report any unexpected, severe, or serious adverse effects to your doctor and to the national pharmacovigilance authority (e.g., CDSCO in India).